Pharmacokinetics and safety of Inotuzumab ozogamicin in patient with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).
Phase of Trial: Phase II
Latest Information Update: 28 Dec 2017
Price : $35 *
At a glance
- Drugs Inotuzumab ozogamicin (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 28 Dec 2017 New trial record
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.